The accelerated approval pathway in oncology: Balancing the benefits and potential harms.
Authors:
- 8 February 2022
- journal article
- editorial
- Published by Elsevier in Journal of Cancer Policy
- Vol. 32, 100323
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experimentJournal of Cancer Policy, 2021
- Evaluation of Selective Outcome Reporting Bias in Efficacy Endpoints in Print and Television Advertisements for Oncology DrugsJournal of General Internal Medicine, 2020
- Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical TrialsJAMA Network Open, 2020
- Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug AdministrationJAMA Oncology, 2019
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncologyEuropean Journal of Cancer, 2019
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and BiologicsJAMA Oncology, 2018
- The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell CancerJAMA Oncology, 2018
- Financial Conflicts of Interest at FDA Drug Advisory Committee MeetingsHastings Center Report, 2018
- Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?BMC Medicine, 2017